The 70-gene test could aid clinicians and patients in determining the optimal treatment course for breast cancer patients with a very low risk of death from the disease.
ODAC approval of Novartis' CAR T-Cell therapy paves the way for its FDA approval as a commercially available treatment for B-cell ALL.
A new study in JCO suggests that genetic variations within AML patients with CD33 may predict their response to gemtuzumab ozogamicin.
Men with prostate cancer and one additional primary cancer may harbor a mutation in a cancer-predisposing gene, but the majority of these men do not meet criteria for clinical genetic testing.
By better understanding the similarities and differences between T-cell receptors, researchers will be better able to develop personalized cancer immunotherapies.
A subpopulation of T cells called tissue resident memory cells may be able to determine which cancer patients' immune systems can mount an effective anti-tumor response
A new clinical trial is recruiting to determine whether a breath testing device can aid in the diagnosis of breast cancer.
An FLT3 inhibitor, gilteritinib, has been found to result in more frequent and sustained responses in patients with relapsed, refractory acute myeloid leukemia.
The FDA has approved dabrafenib in combination with trametinib for the treatment of BRAF V600E mutated non-small cell lung cancer.